Cargando…

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRIS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abbott, Timothy R., Dhamdhere, Girija, Liu, Yanxia, Lin, Xueqiu, Goudy, Laine, Zeng, Leiping, Chemparathy, Augustine, Chmura, Stephen, Heaton, Nicholas S., Debs, Robert, Pande, Tara, Endy, Drew, La Russa, Marie F., Lewis, David B., Qi, Lei S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189862/ https://www.ncbi.nlm.nih.gov/pubmed/32353252 http://dx.doi.org/10.1016/j.cell.2020.04.020

Ejemplares similares

A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses
por: Lin, Xueqiu, et al.
Publicado: (2021)

Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro
por: Zeng, Leiping, et al.
Publicado: (2022)

Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2
por: Hussein, Mouraya, et al.
Publicado: (2023)

CRISPhieRmix: a hierarchical mixture model for CRISPR pooled screens
por: Daley, Timothy P., et al.
Publicado: (2018)

Harnessing the CRISPR-Cas Systems to Combat Antimicrobial Resistance
por: Duan, Cheng, et al.
Publicado: (2021)

Genome-wide CRISPR activation screen identifies JADE3 as an antiviral activator of NF-kB
por: Munir, Moiz, et al.
Publicado: (2023)

Nano-based antiviral coatings to combat viral infections
por: Basak, Soumyadeep, et al.
Publicado: (2020)

Alternative antiviral approaches to combat influenza A virus
por: Wong, Ka Heng, et al.
Publicado: (2022)

CRISPR systems: Novel approaches for detection and combating COVID-19
por: Safari, Fatemeh, et al.
Publicado: (2021)

Interferon-inducer antivirals: Potential candidates to combat COVID-19
por: Bagheri, Ashkan, et al.
Publicado: (2021)

Towards antiviral polymer composites to combat COVID‐19 transmission
por: Mouritz, Adrian P., et al.
Publicado: (2021)

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection
por: Panda, Kingshuk, et al.
Publicado: (2023)

Polyvalent guide RNAs for CRISPR antivirals
por: Bagchi, Rammyani, et al.
Publicado: (2022)

A benchmark of algorithms for the analysis of pooled CRISPR screens
por: Bodapati, Sunil, et al.
Publicado: (2020)

Frontiers in antiviral therapy and immunotherapy
por: Heaton, Steven M
Publicado: (2020)

How CRISPR-Cas System Could Be Used to Combat Antimicrobial Resistance
por: Gholizadeh, Pourya, et al.
Publicado: (2020)

Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics
por: Chan, Kok Gan, et al.
Publicado: (2021)

An Ethical Overview of the CRISPR-Based Elimination of Anopheles gambiae to Combat Malaria
por: Wise, India Jane, et al.
Publicado: (2022)

CRISPR-Based Gene Editing in Acinetobacter baumannii to Combat Antimicrobial Resistance
por: Junaid, Muhammad, et al.
Publicado: (2023)

Surface Alterations to Impart Antiviral Properties to Combat COVID-19 Transmission
por: Siddiquie, Reshma Y., et al.
Publicado: (2020)

Direct-acting antivirals and host-targeting strategies to combat enterovirus infections
por: Bauer, Lisa, et al.
Publicado: (2017)

Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics
por: Liu, Dingjiang, et al.
Publicado: (2021)

Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19
por: England, Corbin, et al.
Publicado: (2023)

The Impact of CRISPR-Cas System on Antiviral Therapy
por: Bayat, Hadi, et al.
Publicado: (2018)

The Application of CRISPR/Cas Systems for Antiviral Therapy
por: Baddeley, Helen J. E., et al.
Publicado: (2021)

Multiplexed genome regulation in vivo with hyper-efficient Cas12a
por: Guo, Lucie Y., et al.
Publicado: (2022)

CRISPR/Cas9: A Novel Weapon in the Arsenal to Combat Plant Diseases
por: Das, Ayan, et al.
Publicado: (2019)

A state-of-the-art review on fucoidan as an antiviral agent to combat viral infections
por: Pradhan, Biswajita, et al.
Publicado: (2022)

Harnessing host–virus evolution in antiviral therapy and immunotherapy
por: Heaton, Steven M
Publicado: (2019)

CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy
por: Chen, Shuliang, et al.
Publicado: (2018)

Phage engineering and phage‐assisted CRISPR‐Cas delivery to combat multidrug‐resistant pathogens
por: Khambhati, Khushal, et al.
Publicado: (2022)

CRISPR-Cas9 System: A Prospective Pathway toward Combatting Antibiotic Resistance
por: Javed, Muhammad Uzair, et al.
Publicado: (2023)

Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
por: Tompa, Dharma Rao, et al.
Publicado: (2021)

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic
por: Khiali, Sajad, et al.
Publicado: (2022)

CRISPR/Cas9: a double-edged sword when used to combat HIV infection
por: Liang, Chen, et al.
Publicado: (2016)

Novel Strategy to Combat Antibiotic Resistance: A Sight into the Combination of CRISPR/Cas9 and Nanoparticles
por: Wan, Fen, et al.
Publicado: (2021)

Mammalian antiviral systems directed by small RNA
por: Takahashi, Tomoko, et al.
Publicado: (2021)

Vaccination strategies to combat novel corona virus SARS-CoV-2
por: Pandey, Satish Chandra, et al.
Publicado: (2020)

Hantaviruses use the endogenous host factor P58(IPK) to combat the PKR antiviral response
por: Wang, Zekun, et al.
Publicado: (2021)

A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19
por: Arunachalam, Karuppusamy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rqshp671rn8ehbp4fk1pss2dd7